The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M

Transaction worth based connected SEC Form 4 weighted mean merchantability terms ($35.32); post-transaction worth based connected March 9, 2026, terms ($35.32).

• How does the merchantability size comparison to Moomaw's caller trading history?
  The 80,000-share merchantability is materially larger than his caller median merchantability transaction of 4,848.5 shares since January 2025, reflecting a azygous commercialized that accounts for a important information of his remaining capableness alternatively than a displacement successful ongoing cadence.

• What was the operation and rationale down the transaction?
  The filing indicates this was an enactment workout with contiguous sale, executed nether a pre-arranged Rule 10b5-1 trading program adopted successful November 2025, accordant with regular liquidity absorption for vested awards.

• What is the interaction connected Moomaw's remaining presumption and imaginable aboriginal sales?
  Direct communal banal holdings declined by 29.74% to 188,954 shares, portion 25,300 banal options stay outstanding and could beryllium exercised for further shares, supporting continued alignment with shareholders.

• What is the marketplace discourse for this transaction?
  The merchantability took spot with Liquidia shares priced astatine astir $35.32, pursuing a 159.4% one-year full instrumentality arsenic of March 9, 2026, and leaves Moomaw with a post-sale nonstop equity presumption valued astatine astir ~$6.8 million.

* 1-year terms alteration calculated utilizing March 9, 2026 arsenic the notation date.

• Products and services see YUTREPIA, an inhaled adust pulverization formulation of treprostinil for pulmonary arterial hypertension, and the organisation of generic treprostinil injection successful the United States.

• The institution generates gross done the development, manufacture, and commercialization of proprietary and generic pharmaceutical products targeting unmet aesculapian needs.

• Primary customers are healthcare providers and institutions treating patients with pulmonary arterial hypertension and related conditions.

Liquidia is simply a biotechnology institution focused connected processing and commercializing therapies for uncommon and superior conditions, with a strategical accent connected pulmonary arterial hypertension. The institution leverages proprietary cause formulation technologies to code unmet diligent needs and grow its portfolio. Liquidia's competitory borderline lies successful its quality to innovate wrong the inhaled therapeutics marketplace and efficiently bring caller treatments to commercialization.